贝伐珠单抗联合XELOX化疗方案治疗老年晚期结直肠癌肝转移患者的临床观察  

Clinical observation of bevacizumab combined with Xelox chemotherapy in the treatment of advanced colorectal cancer liver metastasis in elderly patients

作　　者：卢元丽[1] 张志国[1] 张颖[1] 卢桂龙 李莉[1] 韩磊[1] LU Yuan-li;ZHANG Zhi-guo;ZHANG Ying;HAN Lei(Department of Oncology,People's Hospital of Daxing District(Beijing,102600),China)

机构地区：[1]北京市大兴区人民医院肿瘤科,北京102600

出　　处：《中西医结合肝病杂志》2021年第9期806-808,812,共4页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的:探讨贝伐珠单抗联合XELOX化疗方案治疗老年晚期结、直肠癌肝转移患者的临床疗效及安全性。方法:选取自2018年2月至2019年2月收治的老年晚期结、直肠癌肝转移患者82例,按照随机数字表法分成两组。对照组患者41例,行XELOX方案治疗,观察组患者41例,采用贝伐珠单抗联合XELOX方案治疗。对比两组患者疗效及安全性。结果:观察组患者客观缓解率(ORR)为65.85%,高于对照组的46.34%(P<0.05);观察组患者KPS评分改善率为87.80%,对照组为78.05%(P>0.05);治疗后观察组患者躯体、角色和情绪功能评分显著高于对照组患者(P<0.05),而ALT、AST、指标均低于对照组(P<0.05);观察组患者的不良反应发生率为53.66%,高于对照组的39.02%,但差异无显著性意义(P>0.05)。结论:贝伐珠单抗联合XELOX化疗方案治疗老年晚期结、直肠癌肝转移,可更好地改善患者肝脏功能状态,提高临床疗效。Objective:To investigate the clinical efficacy and safety of bevacizumab combined with XELOX chemotherapy in the treatment of advanced colorectal cancer liver metastasis in elderly patients.Methods:A total of 82 elderly patients with liver metastasis from advanced colorectal cancer admitted from February 2018 to February 2019 was selected and divided into two groups according to random number table method.The control group(n=41)received only the XELOX regimen,while the observation group received bevacizumab combined with the XELOX regimen.The primary and secondary efficacy,liver function,and safety of the two groups were compared.Results:The remission rate in the observation group was 65.85%,which was higher than 46.34%in the control group(P<0.05).The improvement rate of the KPS score was 87.80%and 78.05%in the control group(P>0.05).There were no significant differences in the scores of body,role,cognition,emotion,and social function in QLQ-C30 scale between two groups before treatment(P>0.05),but the scores of body,role,and emotional function in the observation group were significantly higher than the control group after treatment(P<0.05).ALT,AST in two groups before treatment were not statistically significant(P>0.05),after treatment,the observation group was lower than the control group(P<0.05).The incidence of ADR in the observation group was 53.66%,which was lower than that in the control group was 39.02%(P>0.05).Conclusion:Bevacizumab combined with XELOX chemotherapy in the treatment of elderly patients with liver metastasis from advanced colorectal cancer can better improve the functional status and liver function of patients,and enhance the clinical efficacy.

关 键 词：结、直肠癌 肝转移 贝伐珠单抗 XELOX化疗 疗效 

分 类 号：R735[医药卫生—肿瘤]